IGF-1 and Risk of Morbidity and Mortality From Cancer, Cardiovascular Diseases, and All Causes in EPIC-Heidelberg
Authors' conclusion
This large population-based prospective study showed that both individuals with lowest and highest levels of circulating IGF-1 were at increased risk of deaths from cancer, CVD, and all causes. For individuals with low IGF-1, the excess risks of death were more pronounced among individuals with liver cancer and cirrhosis but were also present among individuals without elevated liver enzymes.
Study context
- Population
- EPIC-Heidelberg participants with stored serum samples collected 1994–1998
- Participants
- 7,461 serum samples
- Exposure
- Higher vs lower circulating IGF-1 levels
- Outcome
- Morbidity and mortality from cancer, CVD and all causes, accounting for liver function
- Follow-up
- Median 17.5 years
Methodological detailspopulation-based, prospective, Subcohort of 1810 men and 1890 women; 1668 incident cancers, 1428 cardiovascular diseases (CVD) cases, 2441 deaths
- Population-based
- Prospective
- Subcohort of 1810 men and 1890 women; 1668 incident cancers, 1428 CVD cases, 2441 deaths
Main finding
As reported in the abstract
Higher IGF-1: breast cancer risk
1.25
95% CI 1.06–1.47
Higher IGF-1: prostate cancer risk ([1.09-1.57])
1.31
Observational data: associations, not effects.
Further findings
Participants without indications of liver dysfunction
- U-shaped relationship persisted but was attenuated
Original publication
IGF-1 and Risk of Morbidity and Mortality From Cancer, Cardiovascular Diseases, and All Causes in EPIC-Heidelberg. J Clin Endocrinol Metab. Published 17 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →